NRAS and melanoma: Instead, high-CSD melanoma is characterized by a more miscellaneous set of MAPK pathway mutations, such as BRAF V600K, NRAS, or KIT mutations, or inactivation of the negative regulators of Ras, NF1, or RASA2 [76].